Oftaquix (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these enzymes, it prevents bacterial DNA from unwinding and resealing, leading to bacterial cell death and resolution of the infection.

The appropriate dose of Oftaquix is determined by the prescribing clinician based on the type and severity of the infection, patient age, weight, renal function, and local treatment guidelines. Dosage regimens are not standardized in public information and must be individualized.

Levofloxacin is generally classified as a pregnancy category C medication, meaning risk cannot be ruled out. It is usually avoided unless the potential benefit justifies the risk. Breastfeeding mothers should consult a healthcare professional, as the drug can be excreted in milk and may affect the infant.

To order Oftaquix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Oftaquix (levofloxacin) offers a broad spectrum of activity and a once‑daily dosing option for many infections, which can improve adherence compared with some older fluoroquinolones that require multiple daily doses. Its pharmacokinetic profile provides high tissue penetration, but safety considerations such as tendon risk and QT prolongation are similar across the class.

Oftaquix tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Oftaquix is supplied as oral tablets that are taken with a full glass of water. The tablets should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. Dosing intervals and duration are set by the prescriber.

Serious risks include tendon rupture (especially in the Achilles tendon), QT interval prolongation leading to potentially fatal arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, peripheral neuropathy, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome.

Oftaquix should be avoided in individuals with a known hypersensitivity to levofloxacin or any fluoroquinolone, patients with a history of tendon disorders related to fluoroquinolone use, those with a prolonged QT interval not corrected, and patients receiving concomitant therapy that significantly increases the risk of tendon injury or cardiac arrhythmias.